Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 135

 

Home  | About Us | Editors | Search | Ahead Of Print | Current Issue | Archives | Submit Article | Instructions | Subscribe | Contacts | Login 
     


 
 
Table of Contents
ORIGINAL ARTICLE
Year : 2020  |  Volume : 10  |  Issue : 3  |  Page : 134-139

Recent trends in hospital admissions and outcomes of cardiac Chagas disease in the United States


Department of Cardiology, St. Luke's University Health Network, Bethlehem, PA, USA

Date of Submission09-Oct-2019
Date of Acceptance09-Jun-2020
Date of Web Publication22-Sep-2020

Correspondence Address:
Dr. Jamshid Shirani
Department of Cardiology, St. Luke's University Health Network, 801 Ostrum Street, Bethlehem, PA 18015
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/IJCIIS.IJCIIS_85_19

Rights and Permissions
   Abstract 


Background: Chagas disease (CD), caused by Trypanosoma cruzi, has been increasingly encountered as a cause of cardiovascular disease in the United States. We aimed to examine trends of hospital admissions and cardiovascular outcomes of cardiac CD (CCD).
Methods: Search of 2003-2011 Nationwide Inpatient Sample database identified 949 (age 57±16 years, 51% male, 72.5% Hispanic) admissions for CCD.
Results: A significant increase in the number of admissions for CCD was noted during the study period (OR=1.054; 95% CI=1.028-1.081; P<0.0001); 72% were admitted to Southern and Western hospitals. Comorbidities included hypertension (40%), coronary artery disease (28%), hyperlipidemia (26%), tobacco use (12%), diabetes (9%), heart failure (5%) and obesity (2.2%). Cardiac abnormalities noted during hospitalization included atrial fibrillation (27%), ventricular tachycardia (23%), sinoatrial node dysfunction (5%), complete heart block (4%), valvular heart disease (6%)] and left ventricular aneurysms (5%). In-hospital mortality was 3.2%. Other major adverse events included cardiogenic shock in 54 (5.7%), cardiac arrest in 30 (3.2%), acute heart failure in 88 (9.3%), use of mechanical circulatory support in 29 (3.1%), and acute stroke in 34 (3.5%). Overall, 63% suffered at least one adverse event. Temporary (2%) and permanent (3.5%) pacemakers, implantable cardioverter defibrillators (10%), and cardiac transplant (2.1%) were needed for in-hospital management.
Conclusions: Despite the remaining concerns about lack of awareness of CCD in the US, an increasing number of hospital admissions were reported from 2003-2011. Serious cardiovascular abnormalities were highly prevalent in these patients and were frequently associated with fatal and nonfatal complications.

Keywords: Chagas cardiomyopathy, Chagas heart disease, outcomes, Trypanosoma cruzi


How to cite this article:
Singh A, Cohen B, Sturzoiu T, Vallabhaneni S, Shirani J. Recent trends in hospital admissions and outcomes of cardiac Chagas disease in the United States. Int J Crit Illn Inj Sci 2020;10:134-9

How to cite this URL:
Singh A, Cohen B, Sturzoiu T, Vallabhaneni S, Shirani J. Recent trends in hospital admissions and outcomes of cardiac Chagas disease in the United States. Int J Crit Illn Inj Sci [serial online] 2020 [cited 2020 Oct 24];10:134-9. Available from: https://www.ijciis.org/text.asp?2020/10/3/134/295779




   Introduction Top


Chagas disease (CD) is a parasitic disease caused by the protozoan Trypanosoma cruzi. Transmission occurs most often through an insect vector called the triatomine bug. Inoculation of a bite wound by fecal material from the bug containing the protozoan parasite will then initiate the infection. CD is the most burdensome parasitic disease in the “Region of the Americas” according to the 2015 World Health Organization Global Health Estimates.[1] While historically this was a disease confined to endemic areas of rural Latin America, as international migration increased, the epidemiology of this disease has been changing.[2] Estimating the true burden of CD in the United States (US) is challenging, but one calculation suggested that there are approximately 300,167 individuals with the asymptomatic indeterminate form in this country.[3] Based on this, a conservative estimate of those individuals who have progressed to chronic cardiac CD (CCD) and are currently living in the US is 30,000–45,000.[4] This estimate was calculated using immigration data combined with native country seroprevalence and represents a substantial disease burden. With an ongoing upward trend in international migration, it is likely that the prevalence of CD in the US would be rising.[2] A recent study has estimated the number of affected individuals in the US at 238,091, based on data from the Foreign-Born Hispanic population and the American Community Survey.[5] There is a paucity of epidemiological data regarding CD in the US, and there is also likely a lack of awareness of this disease relative to its increasing burden.[6],[7] By searching a Nationwide Inpatient Sample (NIS) database, we were able to identify all hospitalizations related to CCD within the study period. From this, we aimed to provide temporal admission trends as well as epidemiological and outcomes data including patients' demographics, geographical trends, as well as adverse events and interventions during hospitalization.


   Methods Top


Data source

Data were obtained from the NIS database, a part of the Healthcare Cost and Utilization sponsored by the Agency for Healthcare Research and Quality, for the calendar years 2003 through 2011. The database contains discharge-level data for ~ 8 million hospital stays from ~ 1000 hospitals each year. It is designed to approximate a 20% stratified sample of community hospitals. A total of 46 states, representing ~ 96% of the US population, participate in NIS. Hospital ownership, patient volume, teaching status, urban or rural location, and geographic region are used for stratified sampling, and discharge weights provided by the sponsor are used to obtain national estimates. The database is publicly available and contains de-identified information, and therefore, the study was deemed exempt from institutional research board review. A complete description of the methods can be found in previous publications.[8],[9],[10]

Study population

All hospitalizations with a principal diagnosis ( first or second diagnosis) of CCD were included in the study. This was done using an International Classification of Diseases, Ninth Revision, Clinical Modification code 086.0. The study sample included a total of 949 patients. Patient and hospital characteristics along with outcome parameters were extracted.

Patient and hospital characteristics

Baseline demographic and clinical features studied included both patient-level and hospital-level characteristics. Patient-level characteristics included demographics, primary payer, income quartile, all comorbidity measures for use with administrative data, other cardiovascular comorbidities (tobacco smoking, obesity, dyslipidemia, diabetes, and known heart disease), and psychosocial information. Hospital-level characteristics included hospital location (urban or rural), hospital bed size (small, medium, or large), hospital region (Northeast, Midwest, South, or West), and teaching versus nonteaching status.

Outcome measures

The outcome measures evaluated were inhospital mortality, cardiogenic shock, cardiac arrest, acute systolic or diastolic congestive heart failure, intra-aortic balloon pump use, cardioverter-defibrillator implantation, discharge to a facility other than home, length of stay, cost of hospitalization, and major adverse cardiovascular events. The latter was defined as inhospital mortality, length of hospital stay exceeding 4 days, acute heart failure, cardiogenic shock, and discharge to a facility other than home.

Statistical analysis

Weighted data were used for all statistical analyses. Results were expressed as numbers (%) for categorical variables and mean ± standard deviation for continuous variables. Differences between groups were analyzed with the use of the Student's t-test for continuous variables and the Chi-square test for categorical variables, respectively. Odds ratio (OR) and 95% confidence intervals (CI) were used to report the trend for annual rate of hospital admission for CCD. A two-tailed P < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS statistical software version 20.0 (IBM Corp., Armonk, New York, USA).


   Results Top


Patient population

The demographic and baseline clinical and psychosocial characteristics of 949 patients with CD admitted to hospital between 2003 and 2011 are listed in [Table 1]. The mean age of the 949 patients admitted with CD was 57 ± 16 years, 51% were male, and the majority (73%) were Hispanic. Among cardiovascular risk factors, hypertension, hyperlipidemia, and established coronary disease were the most prevalent. Heart failure (primarily with reduced left ventricular ejection fraction) was present historically in 5.1%. Selected psychosocial, neurologic, systemic, and organ system-specific historical information is also listed in [Table 1]. As shown in [Figure 1], a significant increase in the number of admissions for CCD was noted during the study period (OR = 1.054; 95% CI = 1.028–1.081; P < 0.0001).
Table 1: Demographic, clinical, and psychosocial characteristics of patients admitted with cardiac Chagas disease

Click here to view
Figure 1: Bar graph showing the number of cases of cardiac Chagas disease admitted to the United States hospitals between 2003 and 2011

Click here to view


Insurance, hospital, and cost characteristics

Majority (56%) of the patients admitted with CCD had insurance coverage by Medicare or Medicaid, whereas 19% had private insurance and 12% were self-pay. Income was evenly distributed among quartiles. Overall, 72% of the patients were admitted to hospitals in Southern or Western states, followed by the Northeastern (21%) and Midwestern (7%) states. Nearly 92% of admissions were classified as emergent or urgent rather than elective and one-fourth occurred during weekend days. Large teaching hospitals admitted most of the patients with CCD. The length of stay was 5 ± 16 days at a mean hospital cost of $31,586 ± 97,903.

Electrocardiographic abnormalities

Certain electrocardiographic (ECG) abnormalities in patients admitted with CCD are listed in [Table 2]. Importantly, 27% of the patients were in atrial fibrillation and 23% had ventricular tachycardia. Evidence of sinus node dysfunction was present in 5% and complete heart block was noted in 4%.
Table 2: Electrocardiographic abnormalities among patients admitted with cardiac Chagas disease

Click here to view


Adverse events during hospitalization

Overall, any major adverse event, defined as inhospital mortality, length of hospital stay >4 days, acute heart failure, cardiogenic shock, or discharge to a facility other than home, occurred in 63% of the patients. Majority of these complications were cardiovascular in nature that occurred in 46% of the entire cohort. The latter included rhythm abnormalities (atrial fibrillation in 27% and ventricular tachycardia in 23%), acute heart failure (9%), cardiogenic shock (6%), and cerebrovascular ischemia (8%). In general, 1 in 8 patients admitted with CCD was discharged to a facility other than home following an average hospital stay of 5 days [Table 3].
Table 3: Adverse events and interventions during hospitalization among patients admitted with cardiac Chagas disease

Click here to view


Interventions during hospital stay

Permanent electronic pacemakers were inserted in 3.5% of the patients and 10% required an implantable cardioverter-defibrillator. Mechanical circulatory support was needed in 3.1% and cardiac transplant was performed in 2.1% of the patients [Table 3].


   Discussion Top


Major findings

The present study indicates that an increasing number of patients with CCD are being admitted to hospitals in the US. A large majority of such patients were admitted to hospitals located in the Southern and Western states, possibly reflecting the pattern of settlement of immigrants from endemic areas. The age of patients in this cohort was 57 years, and there was a relatively high prevalence of cardiac risk factors and comorbid conditions such as hypertension (40%), coronary artery disease (28%), hyperlipidemia (26%), and tobacco use (12%). There was a particularly high prevalence of atrial fibrillation (27%) and ventricular tachycardia (23%) in these individuals, and adverse events were frequently (63%) observed during hospitalization. The latter included cardiogenic shock (5.7%), cardiac arrest (3.2%), acute heart failure (9.3%), and acute stroke (3.5%). Permanent electronic pacemakers (3.5%), implantable cardioverter defibrillators (10%), and mechanical circulatory support devices (3.1%) were needed by some patients, and 2.1% underwent cardiac transplant surgery. Inhospital mortality was 3.2%.

Chagas heart disease

Worldwide, CD affects nearly 6–7 million individuals mainly in endemic regions of Latin America at a substantial economic burden.[1],[11],[12] In recent years, migration from these endemic regions has resulted in appearance of the disease in the US and other formerly unaffected areas.[2],[3],[4],[5],[13],[14] It is estimated that over 300,000 individuals living in the US have been infected by T. cruzi[3] and that 30,000–45,000 of them suffer its cardiac consequences.[4] It is likely that the burden of CCD in this country would increase with the upward trend in international migration.[2] An important concern regarding CD is that awareness of the disease is quite low among US physicians,[7] and thus, the number of admissions for CCD, as presented in this report, is likely a gross underestimation of the true burden of the disease.

Comparison with a Brazilian cohort

Despite the increasing number of chronic cases of CD appearing in this country, there has been no large-scale report of the characteristics of such patients. Since CD is not commonly an indigenous disease in the US, it is likely that the epidemiology and clinical characteristics of the disease differ from those in endemic areas. We have compared the findings of the present study with those of a relatively large cohort of patients with CCD from Brazil [Table 4].[15] As shown, the average age of the US cohort is about 10 years older, and they more often have atrial fibrillation or flutter despite much lower incidence of palpitation as a symptom. It can be postulated that some of these differences are related to the absence of reinfection in those who have migrated to nonendemic regions.[16] ECG abnormalities, cardiomegaly, and ventricular apical aneurysm were all reported more frequently in the Brazilian cohort. Other studies have also reported a relatively low prevalence of ECG abnormalities among CD patients in nonendemic areas[17] compared to endemic regions.[18] The prevalence of ECG abnormalities also differs among treated and untreated patients with CCD.[19] Overall, it appears that ECG may be a useful screening tool in endemic regions but not in nonendemic regions.[20]
Table 4: Comparison of the present cohort of patients with cardiac Chagas disease with a regional cohort in Brazil

Click here to view


Clinical implications

The pathogenesis of chronic CCD has been gradually unraveling in recent years.[21],[22] Among various potentially contributing factors, infection-initiated immune response (myocarditis) and coronary microvascular abnormalities (myocyte apoptosis and necrosis) appear to play major roles in the development of CCD.[23],[24],[25],[26],[27] Cardiac involvement in CD evolves from the initial acute myocarditis through a quiescent intermediate form and finally to chronic CCD characterized by conduction abnormalities, sinus node dysfunction, arrhythmias, left ventricular apical aneurysm and thromboembolic events. Sudden death is a relatively common mode of death in patients with CCD and has not been well studied in affected individuals in the US.[28] Such individuals are likely to not be fully represented in the NIS data. The current evidence, as presented in this report, calls for improved systematic surveillance for early recognition of the disease and better understanding of the scope of CD in this country. Finally, strategies to improve awareness of the existence of CD in the US are needed among health-care professionals.

Limitations

This is a retrospective study and thus subject to limitations incurred in uncontrolled design. The data are, however, derived from a large, nationally representative database and thus provide real-life information of epidemiological significance. It is important to bear in mind that the accuracy of the data may have been influenced by the coding practices of individual hospitals. Furthermore, information contained in this sample is administrative in nature and that each admission is considered one individual. It is thus likely that multiple admissions have occurred for some individuals during the study period. Finally, the data did not contain important prognostic information including several components of a commonly used risk score.[15] Despite these limitations, the data represent a unique report on the scope of CCD in the US in recent years.


   Conclusion Top


CCD represents a growing etiology of chronic heart disease with significant morbidity and mortality. The general characteristics of the affected individuals may be significantly different in endemic and nonendemic regions. The effective diagnosis of CCD thus requires familiarity with the unique pathophysiologic features and phenotypic expression of the disease. The current sample of patients with CCD in the US indicates that serious cardiovascular abnormalities are highly prevalent in these patients and are frequently associated with fatal and nonfatal complications.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Research quality and ethics statement

This study was approved by the Institutional Review Board / Ethics Committee. The authors followed applicable EQUATOR Network (http://www.equator-network.org/) guidelines during the conduct of this research project.



 
   References Top

1.
WHO Estimates for 2000-2015. Available from: http://www.who.int/healthinfo/global_burden_disease/estimates/en/. [Last accessed on 2019 Jun 21].  Back to cited text no. 1
    
2.
Rassi A, Rassi A, Marin-Neto JA. Chagas disease. Lancet Lond Engl 2010;375:1388-402.  Back to cited text no. 2
    
3.
Stanaway JD, Roth G. The burden of Chagas disease: Estimates and challenges. Glob Heart 2015;10:139-44.  Back to cited text no. 3
    
4.
Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009;49:e52-4.  Back to cited text no. 4
    
5.
Manne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ. Estimating the Burden of Chagas Disease in the United States. PLoS Negl Trop Dis 2016;10:e0005033.  Back to cited text no. 5
    
6.
Bern C. Chagas' disease. N Engl J Med 2015;373:456-466.  Back to cited text no. 6
    
7.
Stimpert KK, Montgomery SP. Physician awareness of Chagas disease, USA. Emerg Infect Dis 2010;16:871-2.  Back to cited text no. 7
    
8.
Bhatia N, Agrawal S, Garg A, Mohananey D, Sharma A, Agarwal M, et al. Trends and outcomes of infective endocarditis in patients on dialysis. Clin Cardiol 2017;40:423-9.  Back to cited text no. 8
    
9.
Agrawal S, Garg L, Garg A, Mohananey D, Jain A, Manda Y, et al. Recent trends in management and inhospital outcomes of acute myocardial infarction in renal transplant recipients. Am J Cardiol 2017;119:542-52.  Back to cited text no. 9
    
10.
Agrawal S, Garg L, Sharma A, Mohananey D, Bhatia N, Singh A, et al. Comparison of inhospital mortality and frequency of coronary angiography on weekend versus weekday admissions in patients with non-ST-segment elevation acute myocardial infarction. Am J Cardiol 2016;118:632-4.  Back to cited text no. 10
    
11.
Abuhab A, Trindade E, Aulicino GB, Fujii S, Bocchi EA, Bacal F. Chagas' cardiomyopathy: The economic burden of an expensive and neglected disease. Int J Cardiol 2013;168:2375-80.  Back to cited text no. 11
    
12.
Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: A computational simulation model. Lancet Infect Dis 2013;13:342-8.  Back to cited text no. 12
    
13.
Nunes MC, Dones W, Morillo CA, Encina JJ, Ribeiro AL; Council on Chagas Disease of the Interamerican Society of Cardiology. Chagas disease: An overview of clinical and epidemiological aspects. J Am Coll Cardiol 2013;62:767-76.  Back to cited text no. 13
    
14.
Pérez-Molina JA, Norman F, López-Vélez R. Chagas disease in non-endemic countries: Epidemiology, clinical presentation and treatment. Curr Infect Dis Rep 2012;14:263-74.  Back to cited text no. 14
    
15.
Rassi A Jr., Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med 2006;355:799-808.  Back to cited text no. 15
    
16.
Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 2001;1:92-100.  Back to cited text no. 16
    
17.
Sánchez-Montalvá A, Salvador F, Rodríguez-Palomares J, Sulleiro E, Sao-Avilés A, Roure S, et al. Chagas cardiomyopathy: Usefulness of EKG and echocardiogram in a non-endemic country. PLoS One 2016;11:e0157597.  Back to cited text no. 17
    
18.
Rojas LZ, Glisic M, Pletsch-Borba L, Echeverría LE, Bramer WM, Bano A, et al. Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta-analysis. PLoS Negl Trop Dis 2018;12:e0006567.  Back to cited text no. 18
    
19.
Soverow J, Hernandez S, Sanchez D, Forsyth C, Flores CA, Viana G, et al. Progression of baseline electrocardiogram abnormalities in chagas patients undergoing antitrypanosomal treatment. Open Forum Infect Dis 2019;6:ofz012.  Back to cited text no. 19
    
20.
Fernandez AB, Nunes MC, Clark EH, Samuels A, Menacho S, Gomez J, et al. Electrocardiographic and echocardiographic abnormalities in Chagas disease: Findings in residents of rural Bolivian communities hyperendemic for Chagas disease. Glob Heart 2015;10:159-66.  Back to cited text no. 20
    
21.
Tanowitz HB, Machado FS, Jelicks LA, Shirani J, de Carvalho AC, Spray DC, et al. Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). Prog Cardiovasc Dis 2009;51:524-39.  Back to cited text no. 21
    
22.
Machado FS, Jelicks LA, Kirchhoff LV, Shirani J, Nagajyothi F, Mukherjee S, et al. Chagas heart disease: Report on recent developments. Cardiol Rev 2012;20:53-65.  Back to cited text no. 22
    
23.
Jelicks LA, Chandra M, Shirani J, Shtutin V, Tang B, Christ GJ, et al. Cardioprotective effects of phosphoramidon on myocardial structure and function in murine Chagas' disease. Int J Parasitol 2002;32:1497-506.  Back to cited text no. 23
    
24.
Chandra M, Tanowitz HB, Petkova SB, Huang H, Weiss LM, Wittner M, et al. Significance of inducible nitric oxide synthase in acute myocarditis caused by Trypanosoma cruzi (Tulahuen strain). Int J Parasitol 2002;32:897-905.  Back to cited text no. 24
    
25.
Tanowitz HB, Huang H, Jelicks LA, Chandra M, Loredo ML, Weiss LM, et al. Role of endothelin 1 in the pathogenesis of chronic chagasic heart disease. Infect Immun 2005;73:2496-503.  Back to cited text no. 25
    
26.
Chandra M, Shirani J, Shtutin V, Weiss LM, Factor SM, Petkova SB, et al. Cardioprotective effects of verapamil on myocardial structure and function in a murine model of chronic Trypanosoma cruzi infection (Brazil Strain): An echocardiographic study. Int J Parasitol 2002;32:207-15.  Back to cited text no. 26
    
27.
De Souza AP, Tanowitz HB, Chandra M, Shtutin V, Weiss LM, Morris SA, et al. Effects of early and late verapamil administration on the development of cardiomyopathy in experimental chronic Trypanosoma cruzi (Brazil strain) infection. Parasitol Res 2004;92:496-501.  Back to cited text no. 27
    
28.
Sternick EB, Martinelli M, Sampaio R, Gerken LM, Teixeira RA, Scarpelli R, et al. Sudden cardiac death in patients with chagas heart disease and preserved left ventricular function. J Cardiovasc Electrophysiol 2006;17:113-6.  Back to cited text no. 28
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Methods
   Results
   Discussion
   Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed117    
    Printed1    
    Emailed0    
    PDF Downloaded7    
    Comments [Add]    

Recommend this journal